Modgil Shweta, Khosla Radhika, Tiwari Abha, Sharma Kaushal, Anand Akshay
Department of Neurology, Neuroscience Research Lab, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
J Neurosci Rural Pract. 2020 Oct;11(4):573-580. doi: 10.1055/s-0040-1714314. Epub 2020 Aug 20.
Amyotrophic lateral sclerosis (ALS) is a rare motor neuron disease with progressive degeneration of motor neurons. Various molecules have been explored to provide the early diagnostic/prognostic tool for ALS without getting much success in the field and miscellaneous reports studied in various population. The study was aimed to see the differential expression of proteins involved in angiogenesis (angiogenin [ANG], vascular endothelial growth factor [VEGF], vascular endothelial growth factor receptor 2 [VEGFR2], etc), proteinopathy (transactive response DNA binding protein-43 [TDP-43] and optineurin [OPTN]), and neuroinflammation (monocyte chemoattractant protein-1[MCP-1]) based on the characteristics of ALS pathology. Though, suitable panel based on protein expression profile can be designed to robust the ALS identification by enhancing the prognostic and diagnostic efficacy for ALS. A total of 89 ALS patients and 98 nonneurological controls were analyzed for the protein expression. Expression of angiogenic (VEGF, VEGFR2, and ANG), neuroinflammation (MCP-1), and proteinopathy (TDP-43 and OPTN) markers were estimated in plasma of the participants. Proteins were normalized with respective value of total protein before employing statistical analysis. Analysis has exhibited significantly reduced expression of angiogenic, proteinopathy, and neuroinflammation biomarkers in ALS patients in comparison to controls. Spearman's correlation analysis has showed the positive correlation to each protein. Altered expression of these proteins is indicating the prominent function in ALS pathology which may be interdependent and may have a synergistic role. Hence, a panel of expression can be proposed to diagnose ALS patient which may also suggest the modulation of therapeutic strategy according to expression profile of patient.
肌萎缩侧索硬化症(ALS)是一种罕见的运动神经元疾病,运动神经元会进行性退化。人们已经探索了各种分子,以提供用于ALS的早期诊断/预后工具,但在该领域并未取得太大成功,并且在不同人群中进行了各种研究报告。
该研究旨在根据ALS病理学特征,观察参与血管生成(血管生成素[ANG]、血管内皮生长因子[VEGF]、血管内皮生长因子受体2[VEGFR2]等)、蛋白病(反式激活反应DNA结合蛋白43[TDP-43]和视紫质[OPTN])和神经炎症(单核细胞趋化蛋白-1[MCP-1])的蛋白质的差异表达。不过,可以根据蛋白质表达谱设计合适的检测组合,通过提高ALS的预后和诊断效力来加强对ALS的识别。
共分析了89例ALS患者和98例非神经学对照的蛋白质表达情况。在参与者的血浆中评估血管生成(VEGF、VEGFR2和ANG)、神经炎症(MCP-1)和蛋白病(TDP-43和OPTN)标志物的表达。在进行统计分析之前,将蛋白质用各自的总蛋白值进行标准化。
分析显示,与对照组相比,ALS患者中血管生成、蛋白病和神经炎症生物标志物的表达显著降低。Spearman相关性分析显示各蛋白质之间呈正相关。
这些蛋白质表达的改变表明它们在ALS病理学中具有重要作用,可能相互依赖并可能具有协同作用。因此,可以提出一组表达检测组合来诊断ALS患者,这也可能根据患者的表达谱提示治疗策略的调整。